Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature
Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18 F-FDG P...
Saved in:
| Published in: | Cancer imaging Vol. 20; no. 1; pp. 1 - 13 |
|---|---|
| Main Authors: | , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
London
BioMed Central
06.10.2020
BioMed Central Ltd Springer Nature B.V BMC |
| Subjects: | |
| ISSN: | 1470-7330, 1740-5025, 1470-7330 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly
18
F-FDG PET/CT. In neuro-oncology,
18
F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as
18
F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that
18
F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. |
|---|---|
| AbstractList | Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly .sup.18F-FDG PET/CT. In neuro-oncology, .sup.18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as .sup.18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that .sup.18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. Keywords: F-DOPA, Glioma, Primary brain tumor, Systematic review Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18 F-FDG PET/CT. In neuro-oncology, 18 F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18 F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18 F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed.Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of aminoacid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. Abstract Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly 18F-FDG PET/CT. In neuro-oncology, 18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as 18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that 18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain. Metabolic imaging has proven useful for an increasing number of indications in oncology over the past few years, most particularly .sup.18F-FDG PET/CT. In neuro-oncology, .sup.18F-FDG was insufficient to clearly evaluate brain tumors. Amino-acid radiotracers such as .sup.18F-FDOPA were then evaluated in the management of brain diseases, notably tumoral diseases. Even though European guidelines on the use of amino-acid PET in gliomas have been published, it is crucial that future studies standardize acquisition and interpretation parameters. The aim of this article was to systematically review the potential effect of this metabolic imaging technique in numerous steps of the disease: primary and recurrence diagnosis, grading, local and systemic treatment assessment, and prognosis. A total of 41 articles were included and analyzed in this review. It appears that .sup.18F-FDOPA PET holds promise as an effective additional tool in the management of gliomas. More consistent prospective studies are still needed. |
| ArticleNumber | 70 |
| Audience | Academic |
| Author | Somme, François Noël, Georges Bund, Caroline Bender, Laura Namer, Izzie Jacques |
| Author_xml | – sequence: 1 givenname: François orcidid: 0000-0002-1158-7076 surname: Somme fullname: Somme, François email: francois.somme@chru-strasbourg.fr organization: Nuclear medicine Department, Hautepierre University Hospital – sequence: 2 givenname: Laura surname: Bender fullname: Bender, Laura organization: Oncology Department, Hautepierre University Hospital – sequence: 3 givenname: Izzie Jacques surname: Namer fullname: Namer, Izzie Jacques organization: Nuclear medicine Department, Hautepierre University Hospital, Strasbourg University, Unistra/CNRS UMR 7237 – sequence: 4 givenname: Georges surname: Noël fullname: Noël, Georges organization: Radiotherapy Department, Paul Strauss Comprehensive Cancer Center, Strasbourg University, CNRS, IPHC UMR 7178, Centre Paul Strauss, UNICANCER – sequence: 5 givenname: Caroline surname: Bund fullname: Bund, Caroline organization: Nuclear medicine Department, Hautepierre University Hospital |
| BackLink | https://hal.science/hal-04883727$$DView record in HAL |
| BookMark | eNp9kktr3DAUhU1JaR7tH-jKUCjNwqmeltxFYEgzTWAgWUzXQpalGQ22lEr2lPz7yvGEZIYSvLC5_s65D85pduS801n2GYILCHn5PRJQElIABAoAMOEFfZedQMJAwTAGR6--j7PTGDcAoIpX7EN2nEoIlyU6ybrfUZuhdTrG3Jsc8nkx_3l3P8vvr5e58SHv1zrvpJMr3WnXj8xDsJ0Mj3kdpHV5P3Q-xB-5zONj7HUne6vyoLdW_x3hUd7aXgfZD0F_zN4b2Ub9afc-y5bz6-XVTbG4-3V7NVsUilSEFkRCVVdMsZoaQyUCBtGqoaahnBujYNq2xA0AkJKSMlJjKVFTp6V0hSAw-Cy7nWwbLzdiN6_w0oqngg8rIUOas9VCMkOwBopyxEhDGSeAy1IyVpKyomr0upy8Hoa6041KRwiy3TPd_-PsWqz8VjBKIAIkGZxPBusD2c1sIcYaIJxjhtgWJvbbrlnwfwYde9HZqHTbSqf9EAUipIKM04ol9MsBuvFDcOmqiaKwwhQw_kKtZFrWOuPTjGo0FbMSM87TmmPbi_9Q6Wl0Z1UKnbGpvif4-kqw1rLt19G3Q2-9i_sgn0AVfIxBG6FsL0csdbCtgECMURZTlEWKsniKsqBJig6kz8d7U4QnUUywW-nwcpU3VP8AZ7gCGQ |
| CitedBy_id | crossref_primary_10_1177_19714009251345100 crossref_primary_10_3389_fonc_2021_699360 crossref_primary_10_1038_s44303_025_00087_x crossref_primary_10_1007_s00259_023_06225_0 crossref_primary_10_1007_s11060_021_03873_w crossref_primary_10_1016_j_cpt_2023_11_006 crossref_primary_10_1007_s11060_022_04177_3 crossref_primary_10_1186_s12916_024_03831_z crossref_primary_10_1097_PPO_0000000000000758 crossref_primary_10_3390_cancers15164162 crossref_primary_10_3390_cancers17121905 crossref_primary_10_1016_j_neurol_2021_03_006 crossref_primary_10_1007_s40336_024_00646_z crossref_primary_10_1016_j_neurol_2023_03_011 crossref_primary_10_3390_cancers15010090 crossref_primary_10_1097_MNM_0000000000001781 crossref_primary_10_1186_s40644_021_00385_8 crossref_primary_10_1007_s11064_024_04233_6 crossref_primary_10_1053_j_semnuclmed_2024_09_004 crossref_primary_10_3390_jcm14072168 crossref_primary_10_3390_diagnostics14090964 crossref_primary_10_1016_j_drup_2021_100797 crossref_primary_10_1038_s41380_025_02938_w crossref_primary_10_1177_0271678X231168687 |
| Cites_doi | 10.1212/WNL.0b013e31821d74e7 10.1007/s12149-020-01442-1 10.1007/s11060-017-2375-2 10.1097/RLU.0b013e3181becfe0 10.7326/0003-4819-155-8-201110180-00009 10.1007/s12149-020-01443-0 10.4103/0972-3919.103996 10.1007/s00259-003-1205-2 10.1016/j.nucmedbio.2015.01.002 10.1016/j.ijrobp.2013.09.008 10.1007/s11060-012-0986-1 10.1007/s11307-014-0807-3 10.1016/j.ejrad.2014.09.018 10.1259/bjr.20180901 10.1007/s00259-018-4240-8 10.1097/RLU.0000000000000897 10.1093/neuonc/not328 10.1097/MNM.0000000000001184 10.1259/bjr.20150857 10.1007/s11060-018-2877-6 10.1007/s00259-017-3668-6 10.1097/RLU.0000000000001540 10.1186/s13550-020-00645-x 10.1007/s12149-019-01355-8 10.1097/RLU.0b013e318279bcd8 10.1016/j.ejrad.2008.04.018 10.1007/s11060-015-1883-1 10.2967/jnumed.114.140608 10.1097/RLU.0b013e318279fd5a 10.1093/neuonc/nos331 10.1007/s00259-018-4207-9 10.1093/neuonc/not002 10.1158/1078-0432.CCR-13-1440 10.1007/s00259-013-2384-0 10.1007/s11060-020-03407-w 10.1155/2013/690585 10.1259/bjr.20170803 10.1007/s00259-015-3018-5 10.1186/s12885-016-2806-z 10.1259/bjr.20160476 10.1007/s00259-003-1259-1 10.1007/s11060-018-2750-7 10.1016/j.ejrad.2011.01.080 10.1007/s00259-019-04509-y 10.1007/s00330-013-2838-6 10.1007/s00259-013-2678-2 10.1007/s00330-013-3019-3 10.1016/j.neuchi.2019.08.002 10.1007/s12149-018-01328-3 10.1016/j.clineuro.2012.11.002 10.1016/j.phro.2018.06.004 10.1016/j.crad.2011.05.001 10.3747/co.21.1772 10.1016/j.ejrad.2013.09.004 10.3174/ajnr.A3315 10.2967/jnumed.110.078592 10.1093/neuonc/not166 10.1007/s11060-012-0881-9 10.1371/journal.pone.0232141 10.1093/neuonc/not199 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2020 COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s) 2020 – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | C6C AAYXX CITATION 3V. 7X7 7XB 88C 88E 8FE 8FG 8FI 8FJ 8FK ABUWG AFKRA ARAPS AZQEC BENPR BGLVJ CCPQU DWQXO FYUFA GHDGH HCIFZ K9. M0S M0T M1P P5Z P62 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 1XC VOOES 5PM DOA |
| DOI | 10.1186/s40644-020-00348-5 |
| DatabaseName | Springer Nature OA Free Journals CrossRef ProQuest Central (Corporate) ProQuest_Health & Medical Collection ProQuest Central (purchase pre-March 2016) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Technology Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland Advanced Technologies & Computer Science Collection ProQuest Central Essentials Local Electronic Collection Information AUTh Library subscriptions: ProQuest Central Technology collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Healthcare Administration Database PML(ProQuest Medical Library) Advanced Technologies & Aerospace Database ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic Hyper Article en Ligne (HAL) Hyper Article en Ligne (HAL) (Open Access) PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef Publicly Available Content Database Technology Collection ProQuest One Academic Middle East (New) ProQuest Advanced Technologies & Aerospace Collection ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Advanced Technologies & Aerospace Collection ProQuest One Academic Eastern Edition ProQuest Health Management ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) Advanced Technologies & Aerospace Database ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | CrossRef Publicly Available Content Database MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1470-7330 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_a7f43e0c58274d578408a6a7764695cf PMC7541204 oai:HAL:hal-04883727v1 A637886461 10_1186_s40644_020_00348_5 |
| GeographicLocations | United States |
| GeographicLocations_xml | – name: United States |
| GroupedDBID | --- 0R~ 1.S 29B 2WC 4.4 53G 5GY 5VS 6J9 6PF 7X7 88E 8FE 8FG 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABUWG ACGFO ACGFS ACIHN ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AQUVI ARAPS ASPBG AVWKF BAPOH BAWUL BCNDV BENPR BFQNJ BGLVJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EBD EBLON EBS EMB EMOBN F5P FYUFA GROUPED_DOAJ GX1 HCIFZ HMCUK HYE IAO IEA IHR IHW INH INR ITC KQ8 M0T M1P M48 OK1 P2P P62 PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQGLB PQQKQ PROAC PSQYO PUEGO RBZ ROL RPM RSV SOJ SV3 TR2 UKHRP WOQ AAYXX AFFHD CITATION ALIPV 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 1XC VOOES 5PM |
| ID | FETCH-LOGICAL-c4945-4a1cb97c7b5ff5a20f259d5fd588ffc100363d001546574b3aa2db330e9210f3 |
| IEDL.DBID | BENPR |
| ISSN | 1470-7330 1740-5025 |
| IngestDate | Tue Oct 14 18:59:14 EDT 2025 Tue Nov 04 01:33:55 EST 2025 Tue Oct 14 20:33:52 EDT 2025 Thu Sep 04 19:17:18 EDT 2025 Sat Oct 11 13:41:01 EDT 2025 Tue Nov 11 10:29:19 EST 2025 Tue Nov 04 17:53:09 EST 2025 Thu May 22 21:18:37 EDT 2025 Sat Nov 29 06:45:54 EST 2025 Tue Nov 18 21:59:45 EST 2025 Sat Sep 06 07:22:32 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Systematic review Glioma Primary brain tumor F-DOPA |
| Language | English |
| License | Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4945-4a1cb97c7b5ff5a20f259d5fd588ffc100363d001546574b3aa2db330e9210f3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 content type line 14 ObjectType-Feature-3 ObjectType-Evidence Based Healthcare-1 ObjectType-Undefined-1 content type line 23 PMCID: PMC7541204 |
| ORCID | 0000-0002-1158-7076 |
| OpenAccessLink | https://www.proquest.com/docview/2451935078?pq-origsite=%requestingapplication% |
| PMID | 33023662 |
| PQID | 2451935078 |
| PQPubID | 2040154 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a7f43e0c58274d578408a6a7764695cf pubmedcentral_primary_oai_pubmedcentral_nih_gov_7541204 hal_primary_oai_HAL_hal_04883727v1 proquest_miscellaneous_2449178597 proquest_journals_2451935078 gale_infotracmisc_A637886461 gale_infotracacademiconefile_A637886461 gale_healthsolutions_A637886461 crossref_citationtrail_10_1186_s40644_020_00348_5 crossref_primary_10_1186_s40644_020_00348_5 springer_journals_10_1186_s40644_020_00348_5 |
| PublicationCentury | 2000 |
| PublicationDate | 20201006 |
| PublicationDateYYYYMMDD | 2020-10-06 |
| PublicationDate_xml | – month: 10 year: 2020 text: 20201006 day: 6 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London |
| PublicationTitle | Cancer imaging |
| PublicationTitleAbbrev | Cancer Imaging |
| PublicationYear | 2020 |
| Publisher | BioMed Central BioMed Central Ltd Springer Nature B.V BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: Springer Nature B.V – name: BMC |
| References | BJ Fueger (348_CR34) 2010; 51 RS Youland (348_CR24) 2018; 137 A Verger (348_CR30) 2017; 44 K Herrmann (348_CR51) 2014; 16 E Karavaeva (348_CR31) 2015; 17 A Becherer (348_CR14) 2003; 30 H Zhang (348_CR5) 2014; 83 F Walter (348_CR16) 2012; 53 T Zaragori (348_CR37) 2020; 34 J Pallud (348_CR63) 2013; 15 A Santra (348_CR7) 2012; 81 M Ginet (348_CR32) 2020; 47 T Kazda (348_CR40) 2018; 6 F Cicone (348_CR36) 2019; 33 M Nasseri (348_CR49) 2014; 16 M Smits (348_CR59) 2016; 89 MJ Jacob (348_CR10) 2011; 26 TC Oughourlian (348_CR60) 2020; 147 CJ Ledezma (348_CR21) 2009; 71 C Bund (348_CR29) 2017; 42 I Law (348_CR17) 2019; 46 N Dowson (348_CR61) 2014; 21 O Oehlke (348_CR44) 2016; 16 RJ Young (348_CR2) 2011; 76 JH Yoon (348_CR6) 2014; 24 AL Stockham (348_CR1) 2012; 109 S Karunanithi (348_CR52) 2013; 23 S Karunanithi (348_CR54) 2014; 39 F Cicone (348_CR38) 2020; 34 R Kosztyla (348_CR39) 2013; 87 F Fraioli (348_CR55) 2020; 41 L Janvier (348_CR25) 2015; 40 V Villani (348_CR57) 2015; 35 M Wardak (348_CR46) 2014; 41 O Humbert (348_CR50) 2019; 46 T Zaragori (348_CR56) 2020; 10 PF Whiting (348_CR18) 2011; 155 MC Rossi Espagnet (348_CR58) 2016; 89 R Kosztyla (348_CR43) 2019; 92 S Isal (348_CR64) 2018; 91 A Chiaravalloti (348_CR62) 2019; 33 A Chiaravalloti (348_CR23) 2015; 42 J Schwarzenberg (348_CR45) 2014; 20 M Bulik (348_CR4) 2013; 115 S Karunanithi (348_CR53) 2013; 40 C Lapa (348_CR12) 2014; 55 S Karunanithi (348_CR65) 2014; 83 M Tripathi (348_CR11) 2009; 34 P Linhares (348_CR48) 2013; 2013 A Girard (348_CR33) 2020; 15 C Schiepers (348_CR27) 2007; 48 Q-G Zou (348_CR3) 2011; 66 DH Pafundi (348_CR20) 2013; 15 C Kratochwil (348_CR13) 2014; 16 C Nioche (348_CR28) 2013; 38 RS Youland (348_CR15) 2013; 111 CB Patel (348_CR26) 2018; 139 F Cicone (348_CR42) 2015; 42 BM Ellingson (348_CR47) 2017; 134 G Morana (348_CR22) 2014; 55 W Chen (348_CR9) 2006; 47 B Beuthien-Baumann (348_CR19) 2003; 30 JW Dankbaar (348_CR8) 2015; 125 J Todeschi (348_CR35) 2019; 65 S Rose (348_CR41) 2013; 34 |
| References_xml | – volume: 76 start-page: 1918 year: 2011 ident: 348_CR2 publication-title: Neurology. doi: 10.1212/WNL.0b013e31821d74e7 – volume: 34 start-page: 228 year: 2020 ident: 348_CR37 publication-title: Ann Nucl Med doi: 10.1007/s12149-020-01442-1 – volume: 134 start-page: 495 year: 2017 ident: 348_CR47 publication-title: J Neurooncol doi: 10.1007/s11060-017-2375-2 – volume: 34 start-page: 878 year: 2009 ident: 348_CR11 publication-title: Clin Nucl Med doi: 10.1097/RLU.0b013e3181becfe0 – volume: 53 start-page: 393 year: 2012 ident: 348_CR16 publication-title: J Nucl Med Off Publ Soc Nucl Med – volume: 155 start-page: 529 year: 2011 ident: 348_CR18 publication-title: Ann Intern Med doi: 10.7326/0003-4819-155-8-201110180-00009 – volume: 34 start-page: 230 year: 2020 ident: 348_CR38 publication-title: Ann Nucl Med doi: 10.1007/s12149-020-01443-0 – volume: 26 start-page: 139 year: 2011 ident: 348_CR10 publication-title: Indian J Nucl Med IJNM Off J Soc Nucl Med India doi: 10.4103/0972-3919.103996 – volume: 30 start-page: 1004 year: 2003 ident: 348_CR19 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1205-2 – volume: 42 start-page: 355 year: 2015 ident: 348_CR23 publication-title: Nucl Med Biol doi: 10.1016/j.nucmedbio.2015.01.002 – volume: 87 start-page: 1100 year: 2013 ident: 348_CR39 publication-title: Int J Radiat Oncol doi: 10.1016/j.ijrobp.2013.09.008 – volume: 111 start-page: 11 year: 2013 ident: 348_CR15 publication-title: J Neurooncol doi: 10.1007/s11060-012-0986-1 – volume: 17 start-page: 434 year: 2015 ident: 348_CR31 publication-title: Mol Imaging Biol MIB Off Publ Acad Mol Imaging doi: 10.1007/s11307-014-0807-3 – volume: 83 start-page: 2181 year: 2014 ident: 348_CR5 publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2014.09.018 – volume: 92 start-page: 20180901 year: 2019 ident: 348_CR43 publication-title: Br J Radiol doi: 10.1259/bjr.20180901 – volume: 46 start-page: 558 year: 2019 ident: 348_CR50 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-018-4240-8 – volume: 40 start-page: e429 year: 2015 ident: 348_CR25 publication-title: Clin Nucl Med doi: 10.1097/RLU.0000000000000897 – volume: 16 start-page: 1146 year: 2014 ident: 348_CR49 publication-title: Neuro-Oncol. doi: 10.1093/neuonc/not328 – volume: 41 start-page: 517 year: 2020 ident: 348_CR55 publication-title: Nucl Med Commun doi: 10.1097/MNM.0000000000001184 – volume: 89 start-page: 20150857 year: 2016 ident: 348_CR59 publication-title: Br J Radiol doi: 10.1259/bjr.20150857 – volume: 139 start-page: 399 year: 2018 ident: 348_CR26 publication-title: J Neurooncol doi: 10.1007/s11060-018-2877-6 – volume: 44 start-page: 1306 year: 2017 ident: 348_CR30 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-017-3668-6 – volume: 42 start-page: 250 year: 2017 ident: 348_CR29 publication-title: Clin Nucl Med doi: 10.1097/RLU.0000000000001540 – volume: 10 start-page: 56 year: 2020 ident: 348_CR56 publication-title: EJNMMI Res doi: 10.1186/s13550-020-00645-x – volume: 33 start-page: 471 year: 2019 ident: 348_CR62 publication-title: Ann Nucl Med doi: 10.1007/s12149-019-01355-8 – volume: 39 start-page: e121 year: 2014 ident: 348_CR54 publication-title: Clin Nucl Med doi: 10.1097/RLU.0b013e318279bcd8 – volume: 71 start-page: 242 year: 2009 ident: 348_CR21 publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2008.04.018 – volume: 125 start-page: 167 year: 2015 ident: 348_CR8 publication-title: J Neurooncol doi: 10.1007/s11060-015-1883-1 – volume: 55 start-page: 1611 year: 2014 ident: 348_CR12 publication-title: J Nucl Med doi: 10.2967/jnumed.114.140608 – volume: 38 start-page: 81 year: 2013 ident: 348_CR28 publication-title: Clin Nucl Med doi: 10.1097/RLU.0b013e318279fd5a – volume: 15 start-page: 595 year: 2013 ident: 348_CR63 publication-title: Neuro-Oncol. doi: 10.1093/neuonc/nos331 – volume: 46 start-page: 540 year: 2019 ident: 348_CR17 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-018-4207-9 – volume: 15 start-page: 1058 year: 2013 ident: 348_CR20 publication-title: Neuro-Oncol. doi: 10.1093/neuonc/not002 – volume: 20 start-page: 3550 year: 2014 ident: 348_CR45 publication-title: Clin Cancer Res Off J Am Assoc Cancer Res doi: 10.1158/1078-0432.CCR-13-1440 – volume: 40 start-page: 1025 year: 2013 ident: 348_CR53 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2384-0 – volume: 147 start-page: 135 year: 2020 ident: 348_CR60 publication-title: J Neurooncol doi: 10.1007/s11060-020-03407-w – volume: 2013 start-page: 690585 year: 2013 ident: 348_CR48 publication-title: J Oncol doi: 10.1155/2013/690585 – volume: 91 start-page: 20170803 year: 2018 ident: 348_CR64 publication-title: Br J Radiol doi: 10.1259/bjr.20170803 – volume: 42 start-page: 905 year: 2015 ident: 348_CR42 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-015-3018-5 – volume: 16 start-page: 769 year: 2016 ident: 348_CR44 publication-title: BMC Cancer doi: 10.1186/s12885-016-2806-z – volume: 89 start-page: 20160476 year: 2016 ident: 348_CR58 publication-title: Br J Radiol doi: 10.1259/bjr.20160476 – volume: 30 start-page: 1561 year: 2003 ident: 348_CR14 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-003-1259-1 – volume: 137 start-page: 583 year: 2018 ident: 348_CR24 publication-title: J Neurooncol doi: 10.1007/s11060-018-2750-7 – volume: 81 start-page: 508 year: 2012 ident: 348_CR7 publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2011.01.080 – volume: 47 start-page: 1381 year: 2020 ident: 348_CR32 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-019-04509-y – volume: 23 start-page: 2628 year: 2013 ident: 348_CR52 publication-title: Eur Radiol doi: 10.1007/s00330-013-2838-6 – volume: 41 start-page: 1199 year: 2014 ident: 348_CR46 publication-title: Eur J Nucl Med Mol Imaging doi: 10.1007/s00259-013-2678-2 – volume: 24 start-page: 380 year: 2014 ident: 348_CR6 publication-title: Eur Radiol doi: 10.1007/s00330-013-3019-3 – volume: 65 start-page: 357 year: 2019 ident: 348_CR35 publication-title: Neurochirurgie. doi: 10.1016/j.neuchi.2019.08.002 – volume: 33 start-page: 295 year: 2019 ident: 348_CR36 publication-title: Ann Nucl Med doi: 10.1007/s12149-018-01328-3 – volume: 35 start-page: 5117 year: 2015 ident: 348_CR57 publication-title: Anticancer Res – volume: 115 start-page: 146 year: 2013 ident: 348_CR4 publication-title: Clin Neurol Neurosurg doi: 10.1016/j.clineuro.2012.11.002 – volume: 47 start-page: 904 year: 2006 ident: 348_CR9 publication-title: J Nucl Med Off Publ Soc Nucl Med – volume: 55 start-page: 718 year: 2014 ident: 348_CR22 publication-title: J Nucl Med Off Publ Soc Nucl Med – volume: 6 start-page: 94 year: 2018 ident: 348_CR40 publication-title: Phys Imaging Radiat Oncol doi: 10.1016/j.phro.2018.06.004 – volume: 66 start-page: 953 year: 2011 ident: 348_CR3 publication-title: Clin Radiol doi: 10.1016/j.crad.2011.05.001 – volume: 21 start-page: e172 year: 2014 ident: 348_CR61 publication-title: Curr Oncol Tor Ont doi: 10.3747/co.21.1772 – volume: 83 start-page: 219 year: 2014 ident: 348_CR65 publication-title: Eur J Radiol doi: 10.1016/j.ejrad.2013.09.004 – volume: 34 start-page: 758 year: 2013 ident: 348_CR41 publication-title: AJNR Am J Neuroradiol doi: 10.3174/ajnr.A3315 – volume: 51 start-page: 1532 year: 2010 ident: 348_CR34 publication-title: J Nucl Med doi: 10.2967/jnumed.110.078592 – volume: 48 start-page: 1651 year: 2007 ident: 348_CR27 publication-title: J Nucl Med Off Publ Soc Nucl Med – volume: 16 start-page: 603 year: 2014 ident: 348_CR51 publication-title: Neuro-Oncol. doi: 10.1093/neuonc/not166 – volume: 109 start-page: 149 year: 2012 ident: 348_CR1 publication-title: J Neurooncol doi: 10.1007/s11060-012-0881-9 – volume: 15 year: 2020 ident: 348_CR33 publication-title: PLoS One doi: 10.1371/journal.pone.0232141 – volume: 16 start-page: 434 year: 2014 ident: 348_CR13 publication-title: Neuro-Oncol. doi: 10.1093/neuonc/not199 |
| SSID | ssj0029897 |
| Score | 2.2023637 |
| SecondaryResourceType | review_article |
| Snippet | Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations remain.... Abstract Contrast-enhanced magnetic resonance imaging is currently the standard of care in the management of primary brain tumors, although certain limitations... |
| SourceID | doaj pubmedcentral hal proquest gale crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database Publisher |
| StartPage | 1 |
| SubjectTerms | Accuracy Amino acids Bioengineering Brain Brain cancer Brain tumors Cable television broadcasting industry Cancer Cancer Research Evaluation F-DOPA Fluorine isotopes Glioma Gliomas Imaging Imaging techniques Life Sciences Literature reviews Magnetic resonance imaging Management Medical imaging Medicine Medicine & Public Health Metabolism Neurons and Cognition Nuclear Medicine Oncology Positron emission tomography Primary brain tumor Radioactive tracers Radioisotopes Radiology Recurrence (Disease) Review Surgery Systematic review Tumors |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwELWgQogLKl8iUMAgJA4QNY7t2OG2QFc9lLKHBfVm2Y6tVtrNos1uf39nkmzaVAIuXOPJl2fGfk8ePxPy3rFgJfM2LblzqagkS3UQRZp7ZWVeMuFbne5fJ-r0VJ-dlbMbR31hTVgnD9x13KFVUfCQeamBP1UQXyLTtrBKFUDspI84-gLq2ZGpnmqVulS7LTK6OGxg2hIiRaqEgiw6laNpqFXrH8bku-dYEnkDb96ulry1ZNrORNN98rCHkHTSffojcifUj8n97_0i-ROy_NmEuF3gGEZXkTI9TafffswmdHY0p4BRKWA-uhzKXtDmd6c5QR0eGEE32-Vq3Xymll7rPNNujwsa4-2LQY35KZlPj-Zfj9P-VIXUi1LIVFjmXam8cjJGafMsAgOqZKyk1jF6hgo1vGqxVSGVcNzavHKcZ6EEehj5M7JXr-rwnFDutXJOhlgGwH1RW5jaZGAVKxzgOG4TwnZ9bHyvOI4HXyxMyzx0YTq_GPCLaf1iZEI-Dvf0__5X6y_ousEStbLbCxBBpo8g868ISsgbdLzpNp4OGW8mBWrtgxFLyIfWAnMefsDbfusCdAOqZ40sD0aWkKt-1PwOgmv0uceTE4PXcCTlACYv8Rm72DP9gNKYHGWAOIB3nZC3QzM-Hovk6rDaoo0A8q2BIiZEjWJ29MZxS31x3oqKKylYnomEfNpF9_XL_-yAF__DAS_JgxxTE8syigOyt1lvwytyz19uLpr16zaxrwDe60vC priority: 102 providerName: Directory of Open Access Journals – databaseName: SpringerLINK Contemporary 1997-Present dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZoQYgLb0SggEFIHCAiju3Y4bZAVz2UsoKl6s2yHZtW2t2gzW5_Px7nUVIBElzjz0lsz4xn5JnPCL00xGlOrE5LakzKKk5S6ViR5lZonpeE2cjTfXwojo7kyUk564rCmj7bvT-SjJY6qrUs3jZh62EshXAHSFVkynfQ1bDdSVDHL1-PhzCrlKXoy2N-22-0BUWm_sEe75xCOuQvvublTMlLx6VxF5re-r__v41udl4nnrRicgddcau76Pqn7lz9Hlp-a5zfLsDs4dpjIqfp9OPn2QTP9uc4uLU4uIl4OWTKAOZHS1OBDdwxgTfbZb1u3mGNL6ihcVsWA2DovhgInO-j-XR__uEg7S5iSC0rGU-ZJtaUwgrDvec6z3wImiruKy6l95YAqQ2tojtWcMEM1TqvDKWZK0NE6ekDtLuqV-4hwtRKYQx3vnTBVfRSh92QO1KRwgTXj-oEkX5plO1IyuGujIWKwYosVDuNKkyjitOoeIJeD326sf8V_R5WfEACvXZ8UK-_q05blRaeUZdZLkPQXgWjxjKpCy1EwYqSW5-gZyAvqq1VHYyEmhRAzx9AJEGvIgLMRBiA1V21Q5gGINwaIfdGyKDedtT8Isjk6HcPJocKnoHxpcH_PId39CKrOhvUqByYg2jw92WCng_N8HrIq1u5egsYFuJ1GaLKBImRqI--OG5ZnZ1GHnLBGckzlqA3vcBffPzPC_Do3-CP0Y0cdAZyNoo9tLtZb90TdM2eb86a9dOo-T8BSTBQvg priority: 102 providerName: Springer Nature |
| Title | Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature |
| URI | https://link.springer.com/article/10.1186/s40644-020-00348-5 https://www.proquest.com/docview/2451935078 https://www.proquest.com/docview/2449178597 https://hal.science/hal-04883727 https://pubmed.ncbi.nlm.nih.gov/PMC7541204 https://doaj.org/article/a7f43e0c58274d578408a6a7764695cf |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: RBZ dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: M0T dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest advanced technologies & aerospace journals customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: P5Z dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/hightechjournals providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: BENPR dateStart: 20150101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest_Health & Medical Collection customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: 7X7 dateStart: 20150101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: PIMPY dateStart: 20150101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK customDbUrl: eissn: 1470-7330 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0029897 issn: 1470-7330 databaseCode: RSV dateStart: 20000601 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdohxAvfCMCoxiExANEy4cdO7ygDloNaS3RKFPHi-U4MZvUNqNp9_dzl6YpmcReeLHU-PLh3vk-7PPvCHmb-rnmvtFuHKapyzLuuzJnkRsYoXkQ-8xUON2nx2I8ltNpnNQLbmWdVrnViZWizgqDa-QHAeKghOC9yE-Xv12sGoW7q3UJjQ7ZQ6Qy1iV7h4NxctKEXLHclFcRzHM5mPftsRkZHZRgyhhzMXxCkBbp8pZpqhD8Gz3dOcc0yb980OsZlNe2USvrNLz_v-N6QO7VfintbwTpIbmVLx6RO6N65_0xmf8oc7ueoWKkhaW-HLrDL9-SPk0GEwqOLwVHks6bXBqkudwAWdAUq1DQ1XpeLMuPVNMdeDTdHJxBYrx91kA8PyGT4WDy-citSzW4hsWMu0z7Jo2FESm3luvAsxBWZdxmXEprjY-wN2FWOWwRFywNtQ6yNAy9PIaY04ZPSXdRLPJnhIZGijTluY1zcCat1GAvee5nfpSCcxhqh_hbJilTw5hjNY2ZqsIZGakNYxUwVlWMVdwh75t76rHfSH2IvG8oEYC7ulAsf6l6PistLAtzz3AJYX0Gao95UkdaiIhFMTfWIa9QctTmNGujRlQ_QgB_IPId8q6iQEUCAzC6Pg8BfwNCcrUo91uUoABMq_sNSGfrc4_6xwqvoXoOwUO9wmdsxU_VWqpUO9lzyOumGx-PmXeLvFgjDYOIXkLc6RDREvrWG9s9i4vzCqlccOYHHnPIh-302L383wx4fvO3viB3A5y1mMUR7ZPuarnOX5Lb5mp1US57pCOmomplr9YGvWqhBdqRN4E24T-hJ_k6Ss7g18n30z88O2Vk |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwELe2gYAXvhGBwQwC8QDR4sSOHSSEClvVaW3ZQ0F7sxzHZpPaZjTtEH8U_yO-fJVMYm974DW-OHFyd_5dcvc7hF6lxChGtPKTKE19mjHiC0NjP9RcsTAhVJc83d-GfDwWx8fJ0Qb63dTCQFpl4xNLR53lGr6R74bAgxI59CI-nv3woWsU_F1tWmhUanFofv10IVvx4WDPvd_XYdjfn3we-HVXAV_ThDKfKqLThGueMmuZCgPrIoCM2YwJYa0mwNASZSW2iBmnaaRUmKUu7DeJC49s5KbdRNeAVg8yCEfBpI3vElH1cuE08JnDEk2Njoh3C7dvUupDrAaMMMJnnX2wbBfQbgqbJ5CT-RfgvZiueeGfbbkV9u_8Zw_xLrpdY27cq4zkHtow8_voxqjOKniAZl8LY1dTcPo4t5iIvt_f-3LUw0f7E-xAPXYgGc_aPCGQOatIOnAKHTbwcjXLF8V7rPCaGBtXRUEgDKdPW_rqh2hyFWt9hLbm-dw8RjjSgqcpMzYxDihboRwWYIZkJE4d8I2Uh0ijE1LXFO3QKWQqy1BNxLLSI-n0SJZ6JJmH3rbn1Gu_VPoTqForCeTi5YF88V3WvkoqbmlkAs1EyJ31ckEDoWLFeUzjhGnroR1QVFlV6rYuUvZiaE7ghIiH3pQS4CTdArSqaz3cYwC6sY7kdkfSOTfdGX7pjKFzu4PeUMIx2Hoih77PYY5G22XtgQu5VnUPvWiHYXrIKpybfAUyNCFcuJjaQ7xjY50rdkfmpyclCztnlIQB9dC7xhrXF__3C3hy-b3uoJuDyWgohwfjw6foVggOA7JV4m20tVyszDN0XZ8vT4vF89L1YCSv2Er_ALg5twc |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dbxQhECe2msYXvxtXq0Vj4oNueiywsL6dtpcaz_MSz6ZvBFiwTe72mvvo3y_D7m27jZoYX5cfsMAwzISZHwi9McRpTqxOC2pMykpOUulYnmZWaJ4VhNnI030yFKORPD0txtey-GO0--ZKss5pAJamanVwUfp6i8v8YBmOIcZScH2AYEWmfAvdZvBoEPjr309al6uQhdikyvy2Xuc4iqz9rW7eOoPQyGt2582oyRtXp_FEGtz__7E8QPcaaxT3a_F5iG656hHa-drctz9Gsx9L59dTUId47jGRg3Rw-G3cx-OjCQ7mLg7mI561ETSAuajpK7CBtyfwaj2bL5YfsMZXlNG4TpcBMFSftsTOT9BkcDT5dJw2DzSklhWMp0wTawphheHec531fHCmSu5LLqX3lgDZDS2jmZZzwQzVOisNpT1XBE_T0120Xc0r9xRhaqUwhjtfuGBCeqnDKckdKUlugklIdYLIZpmUbcjL4Q2NqYpOjMxVPY0qTKOK06h4gt61dZqx_xX9EVa_RQLtdvwwX_xUzS5WWnhGXc9yGZz5Mig71pM610LkLC-49QnaB9lRdQ5rqzxUPwfa_gAiCXobEaA-wgCsbrIgwjQAEVcHuddBhm1vO8Wvg3x2fve4P1TwDZQyDXbpJbSxEV_V6KalyoBRiAY_QCboVVsMzUO8XeXma8Cw4MfL4G0mSHTEvtNjt6Q6P4v85IIzkvVYgt5vhP-q8z8vwLN_g--jnfHhQA0_j748R3cz2D4Q1pHvoe3VYu1eoDv2cnW-XLyMCuEXrGhchg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Usefulness+of+18F-FDOPA+PET+for+the+management+of+primary+brain+tumors%3A+a+systematic+review+of+the+literature&rft.jtitle=Cancer+imaging&rft.au=Bender%2C+Laura&rft.au=No%C3%83%C2%ABl%2C+Georges&rft.au=Bund%2C+Caroline&rft.au=Somme%2C+Fran%C3%A7ois&rft.date=2020-10-06&rft.pub=BioMed+Central+Ltd&rft.issn=1470-7330&rft.volume=20&rft.issue=1&rft_id=info:doi/10.1186%2Fs40644-020-00348-5&rft.externalDBID=n%2Fa&rft.externalDocID=A637886461 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1470-7330&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1470-7330&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1470-7330&client=summon |